Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexandra-Chloe Villani

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
Current Treatment Options in Cardiovascular Medicine|June 9, 2019
Cardiotoxicity of Immune Checkpoint InhibitorsLili Zhang, Maeve Jones-O'Connor, Magid Awadalla, et al.
The American Journal of Gastroenterology|April 22, 2005
Tumor necrosis factor receptor gene polymorphisms in Crohn's disease: association with clinical phenotypesKevin A Waschke, Alexandra-Chloe Villani, Severine Vermeire, et al.
Iscience|November 13, 2023
Single-cell RNA sequencing of murine ankle joints over time reveals distinct transcriptional changes following <i>Borrelia burgdorferi</i> infectionJennifer D Helble, Michael J Walsh, Julie E McCarthy, et al.
Pediatric Research|November 9, 2021
Single-cell immunophenotyping of the fetal immune response to maternal SARS-CoV-2 infection in late gestationJuan D Matute, Benjamin Finander, David Pepin, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 12, 2021
Altered ratio of dendritic cell subsets in skin-draining lymph nodes promotes Th2-driven contact hypersensitivityHannah L Miller, Prabhakar Sairam Andhey, Melissa K Swiecki, et al.
Journal of the American Heart Association|November 16, 2020
Decreased Absolute Lymphocyte Count and Increased Neutrophil/Lymphocyte Ratio With Immune Checkpoint Inhibitor-Associated MyocarditisZsofia D Drobni, Amna Zafar, Leyre Zubiri, et al.
Journal for Immunotherapy of Cancer|May 16, 2025
Tumor location as a risk factor for severe immune-related adverse eventsSteven M Blum, Ben Ouyang, Leyre Zubiri, et al.
Kidney International Reports|October 26, 2020
Incidence and Clinical Features of Immune-Related Acute Kidney Injury in Patients Receiving Programmed Cell Death Ligand-1 InhibitorsHarish Seethapathy, Sophia Zhao, Ian A Strohbehn, et al.
Journal for Immunotherapy of Cancer|July 3, 2021
Immune-related adverse events associated with immune checkpoint inhibitors: a call to action for collecting and sharing clinical trial and real-world dataKerry L Reynolds, Shaily Arora, Ravikumar Komandur Elayavilli, et al.
Nature|May 17, 2019
Targeting the CBM complex causes T<sub>reg</sub> cells to prime tumours for immune checkpoint therapyMauro Di Pilato, Edward Y Kim, Bruno L Cadilha, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
Current Treatment Options in Cardiovascular Medicine|June 9, 2019
Cardiotoxicity of Immune Checkpoint InhibitorsLili Zhang, Maeve Jones-O'Connor, Magid Awadalla, et al.
The American Journal of Gastroenterology|April 22, 2005
Tumor necrosis factor receptor gene polymorphisms in Crohn's disease: association with clinical phenotypesKevin A Waschke, Alexandra-Chloe Villani, Severine Vermeire, et al.
Iscience|November 13, 2023
Single-cell RNA sequencing of murine ankle joints over time reveals distinct transcriptional changes following <i>Borrelia burgdorferi</i> infectionJennifer D Helble, Michael J Walsh, Julie E McCarthy, et al.
Pediatric Research|November 9, 2021
Single-cell immunophenotyping of the fetal immune response to maternal SARS-CoV-2 infection in late gestationJuan D Matute, Benjamin Finander, David Pepin, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 12, 2021
Altered ratio of dendritic cell subsets in skin-draining lymph nodes promotes Th2-driven contact hypersensitivityHannah L Miller, Prabhakar Sairam Andhey, Melissa K Swiecki, et al.
Journal of the American Heart Association|November 16, 2020
Decreased Absolute Lymphocyte Count and Increased Neutrophil/Lymphocyte Ratio With Immune Checkpoint Inhibitor-Associated MyocarditisZsofia D Drobni, Amna Zafar, Leyre Zubiri, et al.
Journal for Immunotherapy of Cancer|May 16, 2025
Tumor location as a risk factor for severe immune-related adverse eventsSteven M Blum, Ben Ouyang, Leyre Zubiri, et al.
Kidney International Reports|October 26, 2020
Incidence and Clinical Features of Immune-Related Acute Kidney Injury in Patients Receiving Programmed Cell Death Ligand-1 InhibitorsHarish Seethapathy, Sophia Zhao, Ian A Strohbehn, et al.
Journal for Immunotherapy of Cancer|July 3, 2021
Immune-related adverse events associated with immune checkpoint inhibitors: a call to action for collecting and sharing clinical trial and real-world dataKerry L Reynolds, Shaily Arora, Ravikumar Komandur Elayavilli, et al.
Nature|May 17, 2019
Targeting the CBM complex causes T<sub>reg</sub> cells to prime tumours for immune checkpoint therapyMauro Di Pilato, Edward Y Kim, Bruno L Cadilha, et al.
Pageof 3